CSat Investment Advisory’s Ultragenyx Pharmaceutical RARE Stock Holding History

CSat Investment Advisory’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-221	Closed	-$18K	–	857
2020 Q3	$18K	Buy	221 +28	+15%	+$2.32K	﹤0.01%	901
2020 Q2	$15K	Sell	193 -203	-51%	-$13.4K	﹤0.01%	926
2020 Q1	$18K	Buy	396 +70	+21%	+$3.63K	﹤0.01%	749
2019 Q4	$14K	Sell	326 -1,865	-85%	-$76.9K	﹤0.01%	895
2019 Q3	$94K	Buy	2,191 +390	+22%	+$21.2K	0.03%	333
2019 Q2	$114K	Buy	+1,801	New	+$115K	0.04%	277

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

CSat Investment Advisory's RARE Position: Q4 2020 in Review

CSat Investment Advisory sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2020, closing a stake of 221 shares — an estimated $18K sold.

CSat Investment Advisory first reported a position in RARE in Q2 2019 and held it in 6 quarters. The position peaked at $114K in Q2 2019. 253 funds tracked by Wall St. Rank hold RARE as of Q4 2020.

CSat Investment Advisory reported no remaining Ultragenyx Pharmaceutical position as of Q4 2020 after selling out during the quarter.
CSat Investment Advisory sold 221 Ultragenyx Pharmaceutical shares in Q4 2020, an estimated $18K.
CSat Investment Advisory first reported a position in Ultragenyx Pharmaceutical in Q2 2019 and held it in 6 quarters.
CSat Investment Advisory's Ultragenyx Pharmaceutical position peaked at $114K in Q2 2019.
253 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.